Ignite Creation Date:
2024-05-05 @ 5:28 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00467753
Status:
COMPLETED
Last Update Posted:
2021-01-13
First Post:
2007-04-27
Brief Title:
Oxcarbazepine Versus Placebo in Childhood Autism
Sponsor:
University of Medicine and Dentistry of New Jersey
Organization:
Rutgers The State University of New Jersey
Study Overview
Official Title:
Oxcarbazepine Versus Placebo in Childhood Autism
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The proposed study is designed to assess the effectiveness of treatment with Oxcarbazepine vs placebo in childhoodadolescent autism This is a twelve-week study involving twenty subjects between the ages of five and seventeen with a diagnosis of autism
Detailed Description:
The proposed study is designed to assess the effectiveness of treatment with Oxcarbazepine vs placebo in childhoodadolescent autism This is a twelve-week study involving twenty subjects between the ages of five and seventeen with a diagnosis of autism Subjects will receive a psychiatric and medical evaluation by the study psychiatrist to see if shehe has any psychiatric or medical illnesses that would interfere with their ability to participate in this study These evaluations may take up to an hour to complete In addition subjects will be asked to participate in a psychiatric interview designed to determine the childs diagnosis and current problem areas The subjects parent will also be asked to fill out psychiatric questionnaires The interview and questionnaires may take up to 4 hours to complete
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None